文献速递类风湿关节炎

难治性类风湿关节炎相关预测因素与治疗结局:ANSWER队列研究

Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性队列研究纳入日本ANSWER队列3623例接受bDMARDs或JAKi治疗的RA患者,其中450例(12.4%)符合EULAR D2T RA定义前两条标准。多因素Cox分析显示,年龄>75岁、较高RF滴度、较高CDAI、较低MTX剂量及高血压、糖尿病合并症与D2T RA相关;aIL-6R和JAKi较TNF抑制剂因无效停药更少。

要点

  • 3623例RA患者中450例(12.4%)符合EULAR D2T RA定义前两条标准。
  • 年龄>75岁较<65岁HR=0.46,较高RF滴度HR=1.005,较高CDAI HR=1.02。
  • aIL-6R(HR=0.53)和JAKi(HR=0.64)较TNF抑制剂因无效停药更少。

核心结论

  • 较年轻发病、较高RF滴度和合并症预测D2T RA发生;管理D2T RA时aIL-6R和JAKi表现出更优的药物留存。

研究设计与样本

  • 日本ANSWER队列回顾性分析,纳入3623例接受bDMARDs或JAKi治疗的RA患者。
  • 采用多因素Cox比例风险模型分析治疗留存的风险比(HR)。

主要发现

  • 3623例RA患者中450例(12.4%)符合EULAR D2T RA定义前两条标准(本研究定义为D2T RA)。
  • 年龄>75岁较<65岁HR=0.46(95%CI:0.31,0.69),较高RF滴度HR=1.005(95%CI:1.00,1.01)。
  • 较高CDAI HR=1.02(95%CI:1.01,1.03),较低MTX剂量HR=0.97(95%CI:0.95,0.99)。
  • 高血压HR=1.53(95%CI:1.2,1.95),糖尿病HR=1.37(95%CI:1.09,1.73)。
  • aIL-6R(HR=0.53;95%CI:0.37,0.75)和JAKi(HR=0.64;95%CI:0.46,0.90)较TNF抑制剂因无效停药更少;口服糖皮质激素(HR=1.65;95%CI:1.11,2.47)与因毒性不良事件停药增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the predictive factors for difficult-to-treat rheumatoid arthritis (D2T RA) and assess the efficacy of biologic DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi). METHODS: Retrospective analysis was conducted on data from the ANSWER cohort comprising 3623 RA patients treated with bDMARDs or JAKi in Japan. Multivariate Cox proportional hazards modelling was used to analyse the hazard ratios (HRs) for treatment retention. RESULTS: Of the 3623 RA patients, 450 (12.4%) met the first two criteria of the EULAR D2T RA definition (defined as D2T RA in this study). Factors contributing to D2T RA included age over 75 (compared with those under 65, hazard ratio [HR] = 0.46; 95% CI: 0.31, 0.69), higher rheumatoid factor (RF) titres (HR = 1.005; 95% CI: 1.00, 1.01), higher clinical disease activity index (HR = 1.02; 95% CI: 1.01, 1.03), lower methotrexate dosage (HR = 0.97; 95% CI: 0.95, 0.99), and comorbidities like hypertension (HR = 1.53; 95% CI: 1.2, 1.95) and diabetes (HR = 1.37; 95% CI: 1.09, 1.73). Anti-IL-6 receptor antibodies (aIL-6R, HR = 0.53; 95% CI: 0.37, 0.75) and JAKi (HR = 0.64; 95% CI: 0.46, 0.90) were associated with fewer discontinuations due to ineffectiveness compared with TNF inhibitors. Oral glucocorticoid usage (HR = 1.65; 95% CI: 1.11, 2.47) was linked to increased discontinuation due to toxic adverse events. CONCLUSION: Younger onset, higher RF titres, and comorbidities predicted D2T RA development. For managing D2T RA, aIL-6R and JAKi exhibited superior drug retention.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Watanabe R, Ebina K, Gon T, et al. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology (Oxford). 2024. PMID: 38724245. doi:10.1093/rheumatology/keae265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。